AI Briefing#drug-discovery
The latest AI and developer news about #drug-discovery, with the original source and a short summary.
The latest AI and developer news about #drug-discovery, with the original source and a short summary.
The company plans to use robotic labs to generate data for AI models, creating a feedback loop that accelerates molecular synthesis and testing for pharma clients.
The model shares GPT-6 Astra weights and achieves 49.6% on MedChemBench v7, exceeding the High capability threshold in three of four biological evaluations while remaining below Critical thresholds.
Collaborations with partners like Generate Biomedicines and Divergence Labs yielded specific results, including a 70% shorter CAR T-cell design and 35,000 antibody designs generated in one month.
Principal investigators can apply for free access to Anthropic models and direct researcher support for projects in biology and drug discovery.
Working autonomously for 64 hours, Claude produced 17 experimentally validated binders against four scorpion neurotoxins, with all 211 designs released as open data.
The pattern separates cognitive reasoning from GPU-intensive execution using NVIDIA NIMs on GKE and Gemini platform governance.
Quine combines a multimodal world model with an interactive harness to prioritize therapeutic compounds, validated in collaboration with the Broad Institute.
The Amazon Bio Discovery team released three AI-based antibody research papers covering binding strength prediction, developability assessment, and novel drug design.
Microsoft has open-sourced the code and weights of RetroChimera, a retrosynthesis AI published in Nature, under the MIT license.
OpenAI released a research case study demonstrating how Codex and ChatGPT reduced the time for antimicrobial molecule discovery from years to hours.
Outer Biosciences trains AI models using living human skin tissue to discover new skincare compounds.
LEADBOARD, a benchmark applying temporal splits and noise floors to honestly evaluate drug property prediction tools, has been released.
Claude has demonstrated the ability to dramatically increase research speed in protein design and analytical chemistry.
The 'Open Discovery Challenge' for discovering and validating novel malaria drug candidates using AI has been released on Hugging Face.
Nature Reviews analyzed the limitations of AI drug discovery in clinical translation and proposed directions for improvement.
Bristol Myers Squibb (BMS) is significantly expanding its AI infrastructure by adopting NVIDIA DGX SuperPOD to accelerate drug discovery.
Google DeepMind and Isomorphic Labs have announced an AI-driven biosecurity and disease response strategy.
An AI-designed 'super-antigen' vaccine has entered the world's first human clinical trial to counter mutating viruses.
OpenAI has unveiled the **GPT-Rosalind** update, combining GPT-5.5's agentic capabilities to strengthen life sciences research capacity.
Anthropic has launched the 'AI for Science' program, which provides researchers with API credits to accelerate scientific research.
CoCoGraph generated millions of new molecules that obey chemical rules.
An immunology professor predicted that AI-driven acceleration of scientific discovery could make it possible to cure all diseases within 10 years.
AI is accelerating the entire scientific research process, from hypothesis generation to experimental design, changing the paradigm of disease treatment.
OpenAI unveiled GPT-Rosalind, a specialized AI tool for life sciences research, targeting early-stage drug discovery.